New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical’s Tablo® Hemodialysis System

Rhea-AI Summary

Outset Medical (Nasdaq: OM) reported new research from over 1 million Tablo hemodialysis treatments across ~750 facilities and 5-year results from an insourced dialysis program at a large Florida hospital presented at ASN Kidney Week 2025 (Nov 5-8).

Key findings included a 94% reduction in serious cardiac/respiratory events, sustained reductions in central-line bloodstream infections, >95% dialysis staff satisfaction, strong return on investment within 2 years, and >99% achievement of treatment goals for ~10,000 prolonged (23–24h) treatments.

Positive

• 1,000,000+ Tablo treatments analyzed across ~750 facilities
• 94% reduction in serious cardiac or respiratory events (5-year Florida site)
• >95% dialysis staff satisfaction and very high nurse retention (Florida site)
• ROI within 2 years reported for the insourced service line
• >99% achievement of treatment goals for ~10,000 prolonged 23–24h treatments

Negative

• Not indicated for CRRT, limiting use for continuous renal replacement therapy patients
• Dialysate not sterile and not for IV infusion, requiring specific handling and facility protocols

Data from over 1 Million Tablo Treatments Among the Findings Presented at the American Society of Nephrology’s Kidney Week 2025

SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced new research findings from over 1 million Tablo hemodialysis treatments across approximately 750 facilities, and 5-year results from the insourcing of dialysis at a large hospital in Florida.

The findings will be presented at the American Society of Nephrology’s Kidney Week 2025 in Houston, which runs November 5-8. The annual event to showcase the latest advancements in kidney care is attended by more than 12,000 professionals from around the world.

Among the highlights:

• AdventHealth will present data from the conversion of their Ocala, Florida site to an insourced dialysis service line with Tablo. These results over 5 years showed a 94% reduction in serious cardiac or respiratory events, a sustained reduction in central-line blood stream infections, a very high nurse retention rate with greater than 95% dialysis staff satisfaction, and a strong return on investment in the first 2 years of operation.
  
  
• Data from 1 million Tablo treatments across more than 600 facilities support the clinical effectiveness of insourced dialysis in achieving rigorous treatment goals, including up to 24-hour treatments that generally involve the most critical patients. 
  
  
• Data from 10,000 treatments prescribed for more than 23 hours and up to 24 hours, performed at approximately 150 hospitals, showed over 99% achievement of treatment goals with minimal interruptions and rapid resolution of treatment alarms.
  

“We believe these findings provide additional support for an insourced dialysis service line to elevate the standard of care at hospitals serving patients with compromised renal function,” said Michael Aragon, MD, Chief Medical Officer of Outset Medical. “Outset’s growing base of clinical, financial and operational evidence demonstrates that the advantages of insourcing for acute-care facilities can range from hard clinical benefits to significant cost savings and improved patient outcomes.”

The studies can be read in their entirety on the clinical evidence page of the Outset Medical website. Attendees are invited to visit the Outset booth (#709) during the ASN meeting for more information.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding Outset’s beliefs, projections and expectations concerning, among other things, the potential impact and implications of the research results discussed in this press release. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause actual results and other events to differ materially from those expressed or implied in such statements. These risks and uncertainties include risks described in the Risk Factors section of Outset’s public filings with the U.S. Securities and Exchange Commission, including its latest annual and quarterly reports. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Outset disclaims any obligation to update these forward-looking statements.

Indications for use
The Tablo^® Hemodialysis System is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. Treatments must be administered under physician’s prescription and observed by a trained individual who is considered competent in the use of the device. The Tablo Hemodialysis System is also indicated for use in the home. Treatment types available include Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED/ SLEDD), Prolonged Intermittent Renal Replacement Therapy (PIRRT), and Isolated Ultrafiltration. This device is not indicated for continuous renal replacement therapy (CRRT) and is cleared for use for up to 24 hours. The dialysate generated by this device is not sterile and should not be used for intravenous (IV) infusion.

About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo^® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com. Tablo is a registered trademark of Outset Medical, Inc.

Contact
Jim Mazzola
jmazzola@outsetmedical.com

FAQ

What did Outset Medical (OM) present at ASN Kidney Week 2025 on November 5, 2025?

Outset presented research from >1 million Tablo treatments and 5-year results showing clinical and operational benefits of insourced dialysis, including a 94% reduction in serious cardiac/respiratory events.

How did the Florida hospital insourced dialysis program using Tablo affect patient safety and staff metrics?

The 5-year Florida site results reported a 94% reduction in serious cardiac/respiratory events, sustained central-line infection reductions, and >95% dialysis staff satisfaction.

What operational outcomes did Outset report for prolonged 23–24 hour Tablo treatments?

Data from ~10,000 prolonged treatments across ~150 hospitals showed >99% achievement of treatment goals with minimal interruptions.

What financial impact did Outset report for an insourced dialysis service line?

The Florida site reported a strong return on investment within 2 years of implementing an insourced Tablo service line.

Does the Tablo Hemodialysis System have use limitations investors should note?

Yes; Tablo is not indicated for continuous renal replacement therapy (CRRT) and its dialysate is not sterile, so it cannot be used for IV infusion.